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Clinical and molecular characterization of a novel PLIN1 frameshift mutation identified 
in patients with familial partial lipodystrophy. 
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Abstract 
Perilipin-1 is a lipid droplet coat protein predominantly expressed in adipocytes, where it 
inhibits basal and facilitates stimulated lipolysis. Loss-of-function mutations in PLIN1 were 
recently reported in patients with a novel subtype of familial partial lipodystrophy, designated 
as FPLD4. We now report the identification and characterization of a novel heterozygous 
frameshift mutation affecting the carboxy-terminus (439fs) of perilipin-1 in two unrelated 
families. The mutation co-segregated with a similar phenotype including partial 
lipodystrophy, severe insulin resistance and type 2 diabetes, extreme hypertriglyceridaemia 
and non-alcoholic fatty liver disease in both families. Poor metabolic control despite maximal 
medical therapy prompted two patients to undergo bariatric surgery, with remarkably 
beneficial consequences. Functional studies indicated that expression levels of the mutant 
protein were lower than wild type protein and in stably tranfected pre-adipocytes the mutant 
protein was associated with smaller lipid droplets. Interestingly, unlike the previously 
reported 398 and 404 frameshift mutants, this variant binds and stabilizes ABHD5 
expression, but still fails to inhibit basal lipolysis as effectively as wild type perilipin-1. 
Collectively, these findings highlight the physiological need for exquisite regulation of 
neutral lipid storage within adipocyte lipid droplets, as well as the possible metabolic benefits 
of bariatric surgery in this serious disease. 
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Introduction 
Adipocytes within white adipose tissue are uniquely adapted to storing large quantities of 
triglyceride in a single unilocular lipid droplet, providing a highly economical mechanism for 
surplus energy storage. Perilipin-1 is the most abundant phosphoprotein in adipocytes, where 
it constitutively associates with the phospholipid surface monolayer of the lipid droplet [1]. 
Here it regulates lipases, particularly adipose tissue triglyceride lipase (ATGL) and hormone 
sensitive lipase (HSL). ATGL and HSL catalyze the sequential hydrolysis of tri- and then di-
acylglycerol, releasing fatty acids and monoacylglycerol which undergoes a final hydrolytic 
cleavage step by monoacylglycerol lipase (MGL) [2]. Precise regulation of this process is a 
major factor in determining the efficacy of adipose tissue as a lipid buffer in the fed state and 
then subsequently as a source of lipid fuel in the fasting state or during exercise. 
The importance of perilipin-1 function in human metabolism was very recently highlighted 
by the discovery of two heterozygous PLIN1 frameshift mutations affecting the C-terminus 
of the protein in patients with FPLD4 [3]. Both mutations co-segregated with partial 
lipodystrophy, severe insulin resistance, hepatic steatosis and severe dyslipidaemia in three 
French families. Molecular characterization of these mutations demonstrated the inability of 
both mutants to inhibit basal lipolysis. In each case this was attributable to the failure of the 
proteins to effectively prevent ABHD5 (αβ-hydrolase domain containing 5), a co-activator of 
ATGL, from activating ATGL and thus increasing basal lipolysis [4]. Here we report the 
identification, clinical characterization and functional analysis of a third PLIN1 heterozygous 
mutation. 
 
	   4	  
Experimental procedures 
Genetic analysis 
The study was conducted in accordance with the principles of the Declaration of Helsinki and 
was approved by the UK National Health Service Research Ethics Committee. Each 
participant, or a parent in the case of minors, provided written informed consent; minors 
provided oral consent. 
Genomic DNA was isolated from peripheral-blood leukocytes. After excluding mutations in 
the coding regions and splice junctions of LMNA and PPARG, the coding regions and splice 
junctions of PLIN1 were amplified by PCR and sequenced as described previously [3]. 
 
Clinical and biochemical studies 
Blood samples for biochemical assays were taken after an overnight fast. Patients underwent 
skin fold measurements using calipers; results were expressed as the mean of two 
independent measurements and compared to previously reported reference ranges [5]. Dual 
energy X-ray absorptiometry (DEXA) (Lunar Prodigy DXA scanner, software version 12.20) 
was used to evaluate body composition. 
 
Cloning strategy 
Site-directed mutagenesis was performed on pCR-BluntII-TOPO PLIN1 WT [3] using 
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) to generate the 
PLIN1 p.Pro439ValfsX125 (from  here onwards referred to as PLIN1 439fs) mutant using the 
following set of primers 5’-CGGAGCGCAGAGCGTCGGGCGCCGTCCGCCGG-3’ and 5’-
CCGGCGGACGGCGCCCGACGCTCTGCGCTCCG-3’. For the generation of stable cell 
lines, a N-terminally Myc-tagged PLIN1 439fs mutant sequence was subcloned using SalI 
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restriction enzyme sites into the retroviral expression vector pBABEpuro (Clontech) 
harboring a puromycin resistance cassette. For transient transfections the same sequence was 
subcloned into pcDNA3.1 vector using EcoRV-XbaI restriction sites. For bimolecular 
fluorescence complementation (BiFC) assays, pcDNA 3.1 mycPLIN1-439fs-Yc was cloned 
in frame with the C-terminal Yc fragment in previously generated pcDNA3.1-Yc using 
EcoRV-BlpI [4]. The following constructs pcDNA3.1-Yc, pcDNA3.1-Yn, pcDNA3.1 –Yn-
hABHD5, pcDNA3.1-hATGL(S47A)-Yc and pcDNA3.1-MycPLIN1-398fs-Yc were 
previously generated as described in [3, 4].  
 
Cell culture 
Stable cell lines were generated and maintained as described in [3]. In order to study the 
effects of PLIN1 439fs in the presence of WT perilipin-1, a previously described 3T3-L1 pre-
adipocyte stable cell line expressing pLXSN-Flag-PLIN1-WT [3] was subjected to a second 
round of retrovirus transduction with pBABEpuro-myc-PLIN1-WT or mutants. 
 
qRT-PCR 
mRNA was harvested and extracted using a RNeasy Mini Kit (QIAGEN). cDNA synthesis 
was performed using the Superscript II reverse transcriptase enzyme (Invitrogen). 
Quantitative real time-PCR was performed using an ABI TaqMan master mix according to 
the manufacturer’s protocols. The following primer sets were used: hPLIN1 (forward, 5’-
CCCCCTGAAAAGATTGCTTCT-3’; reverse, 5’-GGAACGCTGATGCTGTTTCTG-3’; 
probe, 5’FAM-CATCTCCACCCGCCTCCGCA TAMRA-3’), PPIA (forward, 
5’TTCCTCCTTTCACAGAATTATTCCA-3’; (reverse, 5’- CCGCCAGTGCCATTATGG-
3’; probe, 5’FAM- 6ATTCATGTGCCAGGGTGGTGACTTTACAC-TAMRA-3’). Results 
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were analysed on an ABI PRISM 7900HT (Applied Biosystems) and normalized to 
housekeeping gene (Cyclophilin A) expression levels. 
 
Western Blotting 
For patient adipose tissue protein expression analysis, tissue was homogenized in liquid 
nitrogen and directly lysed in RIPA buffer (SIGMA) containing protease and phosphatase 
inhibitors (Roche).  Protein was quantified using Bio-Rad DC protein quantification kit and 
10 µg of protein lysate was diluted in NuPAGE 4xLDS sample buffer (Invitrogen) containing 
0.05% β-mercaptoethanol and subjected to SDS-PAGE, following transfer onto a 
nitrocellulose membrane. Following transfer, membranes were washed in Tris-buffered saline 
containing 0.1% TWEEN-20 (TBS-T; Sigma-Aldrich), then blocked for 1 hour at room 
temperature (RT) in 3% bovine serum albumin (BSA) or 5% powdered skimmed milk diluted 
in TBS-T. Membranes were further incubated with appropriate primary antibody diluted in 
blocking buffer for 16 hours at 4oC. The following antibodies were used: Perilipin-1 N-
terminal antibody (GP29, Progen), Perilipin-1 C-terminal antibody (Abcam), Perilipin-2 
(GP40, Progen) Myc (Milipore), Flag (Sigma), ABHD5 (Abnova), Calnexin (Abcam) or β-
actin (Abcam). For cellular protein extracts 50 µg of lysate was subjected to SDS-PAGE. 
 
Estimation of protein degradation 
3T3-L1 pre-adipocytes stably expressing either WT or 439fs perilipin-1 were grown until 
confluency and treated with either DMSO as a control or 100 µg/ml cycloheximide, 10 µM 
MG132 and 25 mM NH4Cl  for indicated times before lysis.  
 
Microscopy studies 
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For microscopy studies, cells were seeded into 12-well plates containing slides previously 
rinsed in 70% ethanol. Cells were harvested by rinsing 3 times in PBS and fixing with 4% 
formaldehyde diluted in PBS for 15 minutes (min) at RT. Membrane permeabilisation was 
achieved with 0.5% Saponin for 10 min, followed by blocking in 3% BSA, 0.05% Tween-20 
PBS for 1 hour. Afterwards cells were incubated with primary antibody diluted in blocking 
buffer for 16 hours at 4oC. Then cells were washed 3 times in 0.1% BSA PBS and incubated 
with fluorescent probe conjugated secondary antibody for 1 hour at RT wrapped in foil. 
Where necessary, cells were stained for neutral lipid, by rinsing 3 more times with 0.1% 
BSA-­‐PBS and adding LipidTox Deep Red reagent (Invitrogen) diluted in PBS [1:1000] for 20 
min at RT. Afterwards cells were rinsed in PBS and slides mounted using ProLong Gold  
antifade mounting reagent with DAPI (Invitrogen) for nuclear staining. 
 
Lipid droplet volume measurements 
3T3-L1 pre-adipocytes were treated with 400 µM oleic acid (Sigma) for 48 hours and 
harvested for microscopy studies as described above. LipidTox Deep Red was used to stain 
neutral lipids within lipid droplets, and anti-Myc primary antibody [1:500] dilution in 3% 
BSA, followed by goat anti-mouse Alexa-Fluor-488 fluorescent secondary antibody was used 
for perilipin-1 staining. Cell imaging was performed on a Zeiss LSM 510 Meta confocal 
microscope using the Zen software package (Carl Zeiss Microimaging GmbH). On average 
10 Z-stack images were taken per sample using the 63x objective and lipid droplet volume 
was measured using Volocity 5 software (Perkin Elmer). 
 
Lipolysis 
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Lipolysis experiments were performed as described in [4] in the presence of 6 µM Triascin C 
in order to prevent fatty acid re-esterification. Lipolysis was expressed as a ratio of the 
amount of radioactivity released into the medium over the total amount of incorporated 
radioactivity. 
 
Bimolecular Fluorescence complementation (BiFC) 
BiFC experiments  and signal quantification were performed in cos 7 cells as described in [4, 
6]. In cells expressing perilipin-1 (WT or mutants), ATGL(S47A)-Yc and ABHD5-Yn, total 
YFP signal was normalised to control cells only expressing ATGL(S47A)-Yc and ABHD5-
Yn. All components were normalized for equal protein expression in these experiments. 
 
Statistical analysis 
Quantitative data are presented as mean ± SEM. One-way or two-way analysis of variance 
with post hoc Bonferroni analyses were performed on data at a minimum P<0.05.  
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Results 
Case studies  
Proband A, a 41-year old Caucasian woman (Figure 1A, I.1), was referred to specialist 
physicians in Sydney in 1998 with a ten year history of type 2 diabetes, complicated by 
diabetic retinopathy, extreme hypertriglyceridaemia leading to recurrent pancreatitis, non-
alcoholic fatty liver disease (NAFLD; visualized on ultrasound and CT (computerized 
tomography)) and hypertension. She also had new-onset exercise intolerance (exertional 
dyspnea without chest pain) and muscle cramping. Her diabetes was suboptimally controlled 
despite high dose insulin therapy (>500 units daily). Insulin resistance was confirmed by a 
hyperinsulinaemic-euglycaemic clamp (glucose infusion rate 10.6 µm/min/kg fat free mass). 
The patient had no history of polycystic ovarian syndrome (PCOS) and no difficulty 
conceiving as is apparent from 4 successful pregnancies. Her first pregnancy was 
uncomplicated but her second child was delivered early because of large size for gestational 
age. The diagnosis of diabetes was made after her third pregnancy.  
Her BMI was 31.2 kg/m2 and waist circumference 93 cm. Lipoatrophy was most notable in 
the femorogluteal depot and lower limbs, with abdominal fat largely preserved 
(Supplementary figure 1). Skin-fold measurements (Supplementary figure 2) confirmed 
excess subcutaneous truncal fat and reduced peripheral fat. In addition, DEXA scan (dual 
energy X-ray absorptiometry) confirmed disproportionate fat loss on the limbs (Table 1). Her 
cardiovascular and respiratory examinations were normal. There were no dysmorphic 
features.  
Biochemical investigations revealed severe hypertriglyceridaemia and suboptimal glycemic 
control (Table 1). Her lipoprotein-a level was elevated at 680 mg/L (<300) and leptin level 
was low (Table 1). An echocardiogram revealed a reduced ejection fraction of 30% and a 
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coronary angiogram showed an occluded right coronary artery. Nerve conduction studies and 
electromyography were reported as normal, with only occasional small atrophic fibres. A 
deltoid muscle biopsy was normal. 
The patient’s eldest daughter, now aged 38 (Figure 1A, II.1), was diagnosed with PCOS, 
dyslipidaemia, fatty liver disease (ultrasound), hypertension and type 2 diabetes at age 24 
years. She was initially managed with metformin, but required >500 units/day of insulin 
during the later stages of her first pregnancy, during which she weighed up to 120kg (BMI 
40.1 kg/m2).  She has had four pregnancies, all of which were complicated by hypertension, 
necessitating hospital admission in two pregnancies. All four children are well and have not 
been tested for diabetes.   
The proband’s oldest son (Figure 1A, II.2) has a lipodystrophic phenotype and a BMI of 29.1 
kg/m2 but has not been genetically tested or assessed for diabetes or dyslipidaemia. Her 
middle son (Figure 1A, II.3), aged 33, is centrally obese with a BMI of 39 kg/m2, diabetes 
and mild hypertriglyceridemia. Her youngest son, aged 18 years (Figure 1A, II.4), has type 2 
diabetes, managed with oral medication, and a BMI of 29.1 kg/m2. The proband’s brother, 
aged 55 (BMI of 25.3 kg/m2, Figure 1A, I.2), also has diabetes, a fat mass ratio (FMR) of 2.2 
and skinfold measurements consistent with a lipodystrophic phenotype (Figure 1A).   
In 2005, proband A underwent Roux-en-Y gastric bypass surgery in an effort to improve her 
glycaemic control and hypertriglyceridemia.  This resulted in a 20 kg weight loss, substantial 
reduction in insulin requirements (from 500- to 100 units/day), improved lipid profile and 
reversal of cardiomyopathy on echoardiography. The patient’s daughter also underwent 
Roux-en-Y bypass surgery, resulting in a 55 kg loss of weight (BMI then 22.4 kg/m2), 
cessation of insulin, a subsequent twin birth and two further successful uncomplicated 
pregnancies. In the past 2 years, the proband has been diagnosed with a popliteal artery 
aneurysm, requiring surgical repair and vascular stenting. Her diabetes is currently treated 
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with a lower dose of insulin and a very low fat diet. Hypertriglyceridaemia is controlled with 
gemfibrozil and maxepa. Her echocardiogram is now within normal limits, with an ejection 
fraction increasing from 30% to 59%. 
Proband B, an unrelated 15 year-old boy of Caucasian origin, presented with acanthosis 
nigricans, hepatomegaly and NAFLD (Figure 1A). His BMI was 25.1 kg/m2 (SDS 1.51) with 
central adiposity (waist to height ratio 0.54, normal <0.5) and a striking paucity of limb fat. 
Biochemical investigations showed severe hypertriglyceridaemia with normal total 
cholesterol and low HDL cholesterol levels (0.4 mmol/L). An oral glucose tolerance test 
confirmed the presence of extreme insulin resistance. He had impaired glucose tolerance with 
a 2 hour glucose level of 10.7 mmol/L and an astonishing peak insulin level of 12 396 
pmol/L. His leptin level was low (Table 1). Liver biopsy confirmed significant hepatic 
steatosis. 
The patient’s mother had been diagnosed with PCOS, treated with metformin since age 25 
years, and required in vitro fertilisation for her first pregnancy at age 28 years. She was 
subsequently diagnosed with type 2 diabetes requiring >200 units of insulin daily during 
pregnancy. She continued to have poor glycaemic control, microalbuminuria and NAFLD 
complicated by cirrhosis (on liver biopsy). Lipoatrophy was first recognised clinically in her 
early 40s affecting her limbs and buttocks, with mild central adiposity and prominent deltoid, 
gluteal and calf muscles. She had coarse facial features and androgenic alopecia. She was 
lean (BMI 21.8 kg/m2) and her leptin level was low (Table 1). His father was obese (BMI 37 
kg/m2) with associated dyslipidaemia, but did not have features of severe insulin resistance 
(Figure 1A).  
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Identification of a novel PLIN1 p439fs mutation  
Both probands were wild type for PPARG and LMNA gene sequencing. Candidate gene 
sequencing of all exons and splicing regions of the PLIN1 gene revealed a heterozygous 
deletion of two adjacent nucleotides (thymidine and guanine) within exon 9 
(c.1298_1299delTG), resulting in a translational frameshift (Figure 1B). The mutation is 
predicted to lead to the incorporation of 125 aberrant amino acids from amino acid position 
439 onwards, thus producing an elongated protein (563 amino acids rather than 522) (Figure 
2A). The same mutation was present in both probands, although they are not known to be 
related. The mutation co-segregated with partial lipodystrophy, severe insulin resistance, 
severe dyslipidaemia and NAFLD in both kindreds (Figure 1A). Gestational hypertension 
was prominent in affected women. 
 
Detection of the PLIN1 p439fs mutant protein in patient adipose tissue 
In order to determine whether the frameshift perilipin-1 mutant protein is expressed in vivo, 
samples of both visceral abdominal and subcutaneous adipose tissue were obtained from 
Proband A (at the time of a medically indicated surgical procedure) and subjected to SDS-
PAGE alongside subcutaneous fat samples from gender matched controls (Figure 2B). Both 
the wild type (WT) and 439fs copy of perilipin-1 are detectable with an N-terminal epitope 
targeted antibody, however the higher molecular weight band corresponding to the 439fs 
protein was not detected by an antibody which targets a C-terminal epitope. Notably, the 
levels of WT and particularly the 439fs protein were reduced in the patient compared to 
controls.  
In addition, in both murine and cell models, a decrease in perilipin-1 expression levels in 
adipocytes is typically associated with up-regulation of perilipin-2 expression [7]. In 
	   13	  
accordance with this, our patient manifested an increase in perilipin-2 expression in both 
visceral and subcutaneous adipose tissue when compared to controls (Figure 2B).  
 
Functional characterization of the PLIN1 p439fs mutation 
In order to functionally characterize the effects of the PLIN1 439fs mutation, 3T3-L1 pre-
adipocytes were stably transfected with retroviral vectors expressing pBABEpuro PLIN1 WT 
or the PLIN1 398- or PLIN1 439 frameshift mutants, all bearing a N-terminal Myc tag. 3T3-
L1 pre-adipocytes do not express endogenous perilipin-1, enabling us to directly compare 
their function in the absence of the potentially confounding influence of endogenous 
perilipin-1. The PLIN1 398 frameshift mutation was characterized in previous work and 
served as a ‘negative’ control in these studies [3]. All of the above mutant proteins are 
predicted to have a disordered C-terminus following the frameshift. In keeping with the 
patient biopsy findings, expression levels of the 439fs mutant were lower than those of the 
WT protein despite equivalent mRNA expression levels (Figure 3A,B). Expression of the 
398fs mutant was even lower than that of the 439fs. In the presence of cycloheximide, the 
half-life of the 439fs protein was reduced compared to WT perilipin which is known to be 
particularly stable when associated with lipid droplets (Figure 3C,D)[8-10]. The fact that co-
incubating the stable cell lines exposed to cycloheximide with a proteosomal inhibitor 
(MG132) modestly increased 439fs expression whereas the addition of a lysosomal inhibitor 
(NH4CL) had no discernible affect (Figure 3E), suggests that the 439fs perilipin-1 mutant is 
probably degraded via the proteasome. We also noted that the addition of MG132 increased 
endogenous perilipin-2 expression, which has been previously shown to be degraded via the 
proteosome (Figure 3E), providing useful corroborative evidence for the efficacy and 
specificity of MG132 as a proteosomal inhibitor in these cells. 
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The perilipin-1 439fs mutant is associated with smaller lipid droplets 
Since perilipin-1 is critical for lipid accumulation in adipocytes [11], we assessed the impact 
of expression of the 439fs mutant on lipid droplet size in 3T3-L1 fibroblasts. After 48 hours 
of exposure to medium containing oleic acid, perilipin-1 WT overexpressing cells 
accumulated several large lipid droplets, whereas cells expressing the perilipin-1 439fs 
mutant contained a more heterogeneous population of significantly smaller lipid droplets 
(Figure 4A,B). There was no difference in the ability of C-terminal perilipin-1 mutants to 
target to the lipid droplets (Figure 4A). Perilipin-1 has previously been shown to exert its 
effect on lipid accumulation primarily through the inhibition of basal lipolysis rather than an 
increase in triglyceride synthesis [12]. We thus hypothesized that the 439fs mutant may 
facilitate higher rates of basal lipolysis. In order to test this hypothesis, cells were incubated 
with oleic acid overnight, promoting lipid droplet accumulation, followed by a 4 hour chase 
period in the presence of Triacsin C to inhibit free fatty acid (FFA) re-esterification. Wild 
type (WT) perilipin-1 significantly suppressed FFA release, whereas the 439fs perilipin-1 
mutant did so less effectively, albeit to a greater extent than the 398 perilipin-1 frameshift 
protein (Figure 4C). 
 
Perilipin-1 439fs mutant is able to bind ABHD5 
In an effort to reveal the molecular mechanisms underpinning the 439fs mutant’s failure to 
fully suppress basal lipolysis we employed Bimolecular Fluorescence Complementation 
(BiFC) assays to assess the interaction of the perilipin-1 439fs with ABHD5 (Figure 5). As 
both the 439- and 398fs mutants are expressed at lower levels than WT protein, expression 
plasmids were titrated in order to achieve equal protein expression. YFP signal was 
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reconstituted when ABHD5-Yn was expressed with either WT or the 439fs mutant, but not in 
the presence of the 398fs mutant, implying that the 439fs is still able to interact with ABHD5. 
This is in agreement with previous studies, where amino acids 382-429, equivalent to amino 
acids 380-427 in the human sequence of perilipin-1, were shown to be crucial for ABHD5 
binding [13]. 
One could hypothesize that the conformational change induced by the C-terminal frameshift 
would allow the 439fs mutant to bind ABHD5, but might not necessarily prevent the 
subsequent interaction between ABHD5 and ATGL, as occurs with WT perilipin-1. We 
tested this hypothesis by assessing the ability of the 439fs perilipin-1 mutant to inhibit direct 
interaction between ABHD5 and ATGL. In this assay, expression of ATGL (S47A)-Yc and 
ABHD5-Yn results in bright YFP fluorescence which is reduced by ~70% when either WT or 
the 439fs perilipin-1 mutant is expressed (Figure 6). In contrast, expression of the 398fs 
mutant has no effect on the interaction between ATGL and ABHD5.  
 
Expression of perilipin-1 WT does not rescue 439fs mutant phenotype 
Finally, in an effort to mimic the in vivo consequences of the heterozygous mutation, the 
439fs mutant was co-expressed with flag-tagged wild type perilipin-1 (WT). 439fs protein 
levels were stabilized to some extent by the expression of a WT copy of perilipin-1 (Figure 
7A). The results suggest that increasing the amount of WT perilipin-1 protein increases lipid 
droplet volume (Figure 7C,D), whereas co-expression of either the 439fs or 398fs mutants 
fails to further increase lipid droplet volume. In accordance with these data, measurement of 
basal lipolysis in these cell lines showed less inhibition of basal lipolysis by the 439fs 
perilipin-1 mutant than WT perilipin-1 even in the presence of WT perilipin-1 (Figure 7E). 
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Discussion 
Lipodystophic syndromes are a rare, but fascinating cause of insulin resistant type 2 diabetes. 
The archetypal feature of all lipodystrophies is a lack of adipose tissue, which can either be 
partial or generalized. Nevertheless the consequences of lipodystrophy, which include 
dyslipidaemia, NAFLD, hyperandrogenism and PCOS in women and accelerated 
cardiovascular disease are remarkably similar to those usually associated with obesity as part 
of the metabolic syndrome [14]. This observation in itself constitutes a key piece of evidence 
underpinning the so called ‘lipid overflow hypothesis’ which posits that the capacity of 
mammalian adipose tissue to accommodate surplus lipid is finite, and that when this capacity 
is exceeded, lipids accumulate in ectopic sites, such as the liver and skeletal muscle where 
they are instrumental in causing insulin resistance [15].  
Within the last 15 years several monogenic defects have been causally linked to human 
lipodystrophic syndromes, collectively advancing the understanding of human adipogenesis 
and adipocyte function,  and the systemic metabolic consequences of ‘adipocyte dysfunction’ 
[16, 17]. More recently, our laboratory has reported the consequences of loss-of-function 
mutations in proteins implicated in the formation and functional regulation of adipocyte lipid 
droplets [3, 18]. Interestingly CIDEC and PLIN1 encode LD proteins almost exclusively 
expressed in white adipocytes emphasizing firstly their importance in determining the unique 
properties of adipocyte LDs and secondly the ‘whole organism’ consequences of dysfunction 
of proteins primarily expressed in adipocytes (perilipin-1 is also expressed in adrenal cells, 
and both proteins can be expressed in steatotic hepatocytes). 
The original description of patients with FPLD4 due to PLIN1 mutations was based on a 
description of 6 affected subjects. In order to better understand this novel phenotype we have 
attempted to identify more affected subjects. These efforts enabled us to identify another two 
probands and four affected relatives with a different PLIN1 mutation (439fs) to those 
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previously reported. The key features of patients with the 439fs mutant include lack of 
peripheral fat depots, severe insulin resistance and extreme hypertriglyceridaemia. These 
features are consistent with what was observed in patients with either the PLIN1 398 or 404 
frameshift mutations. The effect of bariatric surgery on the metabolic phenotype of Proband 
A was particularly striking. She experienced a 20 kg weight loss, with an 80% reduction in 
insulin requirements, improved lipid profile, reversal of cardiomyopathy and improvement in 
muscle strength. Her daughter exhibited a similar improvement in metabolic profile. These 
metabolic improvements are consistent with case reports describing the response to bariatric 
surgery in other forms of partial lipodystrophy [19-21] and highlight the importance of 
‘relieving’ the energetic stress imposed upon their dysfunctional adipocytes. The beneficial 
symptomatic and functional effect of bariatric surgery on cardiac function in obese patients 
with cardiomyopathy has been described in a limited number of reports, but not yet in 
patients with lipodystrophy [22].  
Functional studies of the 439fs mutant suggest that it is associated with smaller lipid droplets 
and higher basal lipolytic rates. These data are consistent with previously reported studies by 
Garcia et al, who observed less triglyceride accumulation in cells over-expressing an 
artificially generated perilipin-1 truncation mutant which truncates the protein at an amino 
acid very close to the site of our 439fs mutant, namely E427 stop [11]. However, 
understanding why the 439fs mutant is associated with higher basal lipolytic rates is more 
complex than was the case for the previously reported human mutants (398 and 404fs) as 
those fail to bind and stabilize ABHD5, whereas our studies suggest that the 439fs mutant 
does bind ABHD5, stabilize its expression and sequester it from ATGL. One possible 
explanation might be the strikingly reduced expression of the 439fs mutant, which was 
observed in tissue samples from Proband A and in transfected cells. The aberrant C-terminus 
of 439fs mutant protein is likely to be disordered, which would account for its propensity to 
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degradation as occurs with many mutant proteins [23]. Interestingly, even partial loss of 
perilipin-1 is sufficient to reduce fat mass as observed in Plin1 heterozygous knockout mice 
[7]. Absent perilipin-1 expression in Plin1 null mice was also associated with concomitant 
up-regulation of perilipin-2 [7, 24]. Thus the observed up-regulation of perilipin-2 expression 
in fat biopsies from Proband A provides further evidence for reduced total perilipin-1 
expression in vivo. We cautiously conclude therefore that reduced perilipin-1 expression is 
likely to be an important factor in the phenotype observed in patients with the 439fs PLIN1 
mutation. It is also very likely that the C-terminus of perilipin-1 has additional, as yet 
incompletely understood, biological functions which are likely to be impaired by this 
mutation.  
In summary, we report the clinical and molecular characterization of a novel PLIN1 
frameshift mutation in two kindreds with FPLD4. The severity of metabolic disease seen in 
affected patients further highlights the importance of precise lipolytic regulation in adipose 
tissue in human health. Finally, the highly beneficial response of two patients with this 
disorder to bariatric surgery emphasizes the importance of weight loss in these patients. 
Surgery lessens ectopic fat deposition and offers at least one useful management option for an 
otherwise devastating metabolic illness.  
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Figure Legends 
Figure 1. A heterozygous PLIN1 439fs mutation co-segregates with insulin-resistant 
diabetes, dyslipidemia and partial lipodystrophy. A) Family pedigrees of probands A and 
B showing co-segregation of p.Pro439ValfsX125 with insulin resistance, dyslipidemia, 
lipodystrophy and, to a lesser extent, hypertension. M1 denotes PLIN1 p.Pro439ValfsX125 
mutation, N- wild type and ND- not determined. Probands are denoted by an arrow.  B) 
Sequence chromatogram confirming deletion of a TG base pair within exon nine (nucleotide 
1298) and the predicted consequences of this mutation on the amino acid sequence of 
perilipin-1. 
Figure 2. Predicted consequences of the perilipin-1 439fs mutant and documentation of 
its expression in adipose tissue. A) A schematic representation of the expected effects of the 
perilipin-1 439fs mutation on the protein domain organisation. B) Immunoblots showing 
perilipin-1 and 2 expression in adipose tissue samples from proband A (these include a 
visceral fat and subcutaneous leg fat sample) compared with expression in subcutaneous 
abdominal fat samples from two control samples. The N-terminal perilipin-1 antibody (GP29) 
detects both mutant (arrow) and wild type perilipin-1, whereas the C-terminal antibody only 
detects wild type perilipin-1. Calnexin was used as a loading control. 
 
Figure 3. Expression of the perilipin-1 439fs mutation in stably transduced 3T3-L1 pre-
adipocyte cell lines.  3T3-L1 pre-adipocytes stably expressing either empty vector (EV) or 
N-terminally Myc tagged perilipin-1 wild type (WT), perilipin-1 439fs (439fs) and 398fs 
(398fs) mutants were generated as described in the materials and methods.  A) Immunoblot 
analysis of perilipin-1 expression using an anti-Myc antibody, β-actin was used as a loading 
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control. B) mRNA levels of hPLIN1 normalized to mCyclophilinA expression. C, D) Stably 
transfected 3T3-L1 pre-adipocytes expressing WT and 439fs perilipin-1 were grown to 
confluency and treated with 100 µg/ml cycloheximide for the indicated times. Cells were 
lysed and perilipin-1 expression levels were detected by immunoblotting with anti-Myc 
antibody and β-actin to assess loading. C) A representative image is shown. D) 
Quantification of perilipin-1 WT and 439fs expression levels from 3 independent 
experiments. Data represented as mean ±SEM. E) Stably transfected 3T3-L1 pre-adipocytes 
expressing WT and 439fs perilipin-1 were grown to confluency and treated with 100 µg/ml 
cycloheximide and/or 10 µM MG132, 25mM NH4Cl for 24 hours. Cells were lysed and 
perilipin-1 and 2 expression levels detected by immunoblotting, β-actin was used to assess 
loading. A representative image is shown. *-Non-specific band, arrow denotes corresponding 
band. 
 
Figure 4. Characterisation of the impact of the perilipin-1 439fs mutant on lipid droplet 
morphology and lipolysis. 
A) Stable cell lines were treated with 400 µM oleic acid for 48 hours, fixed and stained with 
anti-Myc and anti-mouse-Alexa488 for perilipin-1 (green), LipidTox DeepRed for lipid 
droplets (red) and DAPI for nuclei (blue); scale bar 10 µm. B) Lipid droplet (LD) volume 
was measured by taking an average of 10 Z-stacks at 63x magnification with 2-3 cells per 
focal plane, followed by analysis using the Volosity 5 software (Perkin Elmer). Results from 
three independent experiments are expressed as mean±SEM. C) Stable cell lines were loaded 
with 14C oleic acid for 16 hours in order to label the intracellular triglyceride pool. Release of 
incorporated radioactivity was measured over 4 hours in the presence of 6 µM Triascin C to 
prevent fatty acid re-esterifiation. Lipolysis is expressed as the percentage of released 
radioactivity in the medium over total radioactivity incorporated. Results from three 
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independent experiments are expressed as mean±SEM. In B and C, post hoc pairwise 
comparisons are shown versus EV and between pairs, indicated with an overlying bar. *** 
P<0.001 **P<0.01.  
 
Figure 5. The perilipin-1 439fs mutant interacts with ABHD5 on the surface of lipid 
droplets. Interaction between perilipin-1 (wild type (WT), 439fs or 398fs) and ABHD5 was 
assessed using bimolecular complementation (BiFC) in COS-7 cells after normalizing for 
equal expression of each protein. A) Yn-ABHD5 and Myc-PLIN1-Yc (wild type (WT), 439fs 
or 398fs mutants) were co-transfected in COS-7 cells and stained with anti-Myc and anti-
mouse-Alexa594 for perilipin-1 (green) and DAPI for nuclei (blue). The presence of YFP 
BiFC signal indicates direct interaction between perilipin-1 and ABHD5; scale bar 10µm. B) 
The YFP BiFC signal was quantified as described in materials and methods. Results from 
three independent experiments are expressed as mean±SEM, where post hoc comparison is 
shown vs WT. ns-not significant ** P<0.001. C) The amount of Myc-perilipin-1 and ABHD5 
expressed was assessed by immunoblotting. β-actin was used as a loading control. 
 
Figure 6. The perilipin-1 439fs mutant inhibits the interaction between ATGL and 
ABHD5.  Interaction between ATGL and ABHD5 was assed using BiFC in COS-7 cells after 
normalizing for equal expression of each protein. A) Yn-ABHD5, ATGL (S47A)-Yc and 
myc-PLIN1 (wild type (WT), 439fs or 398fs mutants) were co-transfected in COS-7 cells and 
stained with anti-Myc and anti-mouse-Alexa594 for perilipin-1 (green) and DAPI for nuclei 
(blue). The presence of YFP BiFC signal indicates a direct interaction between ATGL and 
ABHD5; scale bar 10 µm. B) The YFP BiFC signal was quantified as described in materials 
and methods. Results from three independent experiments are expressed as mean±SEM. Post 
hoc pairwise comparisons are shown versus EV. ns-not significant ** P<0.001. C) 
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Expression of Myc-perilipin-1, ABHD5 and ATGL was assessed by immunoblotting. β-actin 
was used as a loading control. 
 
Figure 7. Characterisation of the consequences of the PLIN1 439fs mutation in pre-
adipocytes co-expressing wild type perilipin-1. 3T3-L1 pre-adipocytes stably expressing 
pLXSN-Flag-PLIN1-WT (wild type) were infected with pBABEpuro EV or Myc-PLIN1 
WT, PLIN1 439fs and PLIN1 398fs mutants as described in materials and methods.  A) 
Immunoblot analysis of perilipin-1 expression using an anti-Myc or anit-Flag antibody. β-
actin was assessed as a loading control. B) mRNA levels of total hPLIN1 normalized to 
mCyclophilinA expression. C) Stable cell lines were treated with 400 µM oleic acid for 48 
hours, fixed and stained with anti-Myc and anti-mouse-Alexa488 for perilipin-1 (green), 
LipidTox DeepRed for lipid droplets (red) and DAPI for nuclei (blue); scale bar 10 µm. D) 
Lipid droplet (LD) volume was measured by taking the average of 10 Z-stacks at 63x 
magnification with 2-3 cells per focal plane, followed by analysis using Volosity 5 software. 
Results from three independent experiments are expressed as mean±SEM. E) Stable cell lines 
were loaded with 14C oleic acid for 16 hours in order to label the intracellular triglyceride 
pool. Release of incorporated radioactivity was measured over 4 hours in the presence of 6 
µM Triascin C to prevent fatty acid re-esterifiation. Lipolysis is expressed as the percentage 
of released radioactivity in the media over the total radioactivity incorporated. Results from 
three independent experiments are expressed as mean as mean±SEM. In D and E, post 
hoc pairwise comparisons are shown versus EV, and between pairs, indicated with an 
overlying bar. * P<0.05; **P<0.01; *** P<0.001. 
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Table 1. Clinical and biochemical characterization of probands and relatives with the PLIN1 439fs mutation. 
 
  Proband A I.2 II.1 II.4 Proband B Mother Reference Range 
PLIN1 mutation 439fs 439fs 439fs 439fs 439fs 439fs   
Age (years) 56 55 38 18 15 48   
Gender Female Male Female Male Male Female   
BMI (kg/m2) 31.2 25.4 30.4  29.1 25.1  21.8   
Fat distribution 
Limb and 
femorogluteal 
lipodystrophy 
Limb and 
femorogluteal 
lipodystrophy 
Limb and 
femorogluteal 
lipodystrophy 
Limb and 
femorogluteal 
lipodystrophy 
Limb and 
femorogluteal 
lipodystrophy 
Limb and 
femorogluteal 
lipodystrophy 
  
Polycystic ovary 
syndrome - NA + NA NA             +   
Fatty Liver + ND + ND + +   
Pancreatitis + - - - - +   
Cardiomyopathy + - - - - +   
DEXA FMR  1998- 1.4; 2005- 1.9; 2010- 1.9 2.2 ND ND ND  
 
ND 
Lipodystrophy if 
FMR>1.2 
Total Cholesterol 
(mmol/L) 10.5 4.6 5.5 4.1 4.4 3.0 <5.2 
Triglyceride 
(mmol/L) 56.1 2 6.1 2.3 26.3 2.2 <1.7 
HbA1c (mmol/mol) 
(%) 63 (7.9%) 79 (9.4%) 59 (7.5%) 51 (6.8%) 32 (5.1%) 
 
97 (11.0%) 
 
<53.0 (7.0%) 
Glucose (mmol/L) 11.3 6.4 ND 4.8 5.1 14.4 <6.1 
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Insulin (pmol/L) ND 17 ND ND 285 169 <60 
Leptin (ng/mL) 2.9 2.8 3.8 ND 2.1 3.6 3.7-11.1 
 
BMI, body mass index; NA, not applicable; ND, not determined; DEXA, dual X–ray absorptiometry; FMR ,Fat Mass Ratio (% fat trunk to % fat lower limb ratio); 
  
Supplementary Figure 1. Clinical photographs of Proband A. 
 
The images show the distinctive lipodystrophic fat distribution, including retention of 
truncal fat and fat loss in the limbs and femorogluteal region. 
 
 
Supplementary Figure 2. Skin fold thickness measurements in Proband A.  
 
Measurements were repeated on several occasions, each of which is represented in a 
different colour (at age 41 years (red), 42 years (yellow), 43 years (green) and 53 
years (blue)). Results are expressed as the mean of two independent measurements 
and compared to previously reported reference ranges 5th percentile and 95th 
percentile in black line. 
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